AMGen (formerly Applied Molecular Genetics) is a multinational biopharmaceutical company headquartered in Thousand Oaks, California, and it is the largest independent biotechnology company in the world. Amgen's largest selling product lines are Neulasta and Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy, and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Nplate, Vectibux, Sensipar/Mimpara, Prolia and XGEVA.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Limited, UCB, Novartis AG, Bayer HealthCare Pharmaceuticals Inc., and Merck & Co. Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.
(Summary) (Company) (Chart)
| 2 February 2016 Price $150.11 1yr Target $185.00 Analysts 15 Dividend $4.00 Payout Ratio 47.78% 1yr Cap Gain 23.24% Yield 2.66% 1yr Tot Return 25.90% | EPS (ttm) $8.37 EPS next yr $12.10 EPS next 5yr 9.53% 1yr Price Support $115.31 P/E 17.93 PEG 1.88 Beta 0.78 Market Cap $113.23 Bil Revenues $21.46 Bil Earnings $6.43 Bil Profit Margin 29.96% | 1yr EarnGR 54.92% 3yr EarnGR 23.17% 5yr EarnGR 16.72% 1yr DivGR 21.53% 3yr DivGR 29.60% 5yr DivGR --- Quick Ratio 5.10 Current Ratio 5.40 Debt/Equity 1.14 ROA 9.20% ROE 23.90% |
My Perspective
Amgen has been moving sideways in a very broad band since the middle of 2014. For swing traders, this has been an ideal platform for trading the stock. This is also the kind of situation that lends itself to option sellers. But it's not the best situation for those investors who have simply held the stock over all these years.
But this stagnation has allowed the company to grow its fundamentals while the price of the stock remains range bound. This has allowed some of those fundamentals that were relatively high to come back within a range that makes the stock more desirable.
With a P/E ratio under twenty, a dividend yield above two percent, and a payout ratio less than fifty percent, this stock is now on a list of stock I'll start to accumulate. This company will fit in nicely with my shares of Gilead Sciences and I expect these two companies to provide a growing dividend and a nice return on investment capital.
But this stagnation has allowed the company to grow its fundamentals while the price of the stock remains range bound. This has allowed some of those fundamentals that were relatively high to come back within a range that makes the stock more desirable.
With a P/E ratio under twenty, a dividend yield above two percent, and a payout ratio less than fifty percent, this stock is now on a list of stock I'll start to accumulate. This company will fit in nicely with my shares of Gilead Sciences and I expect these two companies to provide a growing dividend and a nice return on investment capital.
Print 
PDF
RSS Feed
